M
Michel Clanet
Researcher at University of Toulouse
Publications - 126
Citations - 18620
Michel Clanet is an academic researcher from University of Toulouse. The author has contributed to research in topics: Multiple sclerosis & Expanded Disability Status Scale. The author has an hindex of 42, co-authored 126 publications receiving 16617 citations. Previous affiliations of Michel Clanet include Centre Hospitalier Universitaire de Toulouse & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized phase II trial
Ludwig Kappos,Giancarlo Comi,Hillel Panitch,Joel Oger,Jack P. Antel,Paul J. Conlon,Lawrence Steinman,Alexander Rae-Grant,John Castaldo,Nancy Eckert,Joseph Guarnaccia,Pamela Mills,Gary Johnson,Peter A. Calabresi,Carlo Pozzilli,Stefano Bastianello,Elisabetta Giugni,Tatiana Witjas,Patrick J. Cozzone,Jean Pelletier,Dieter Pöhlau,Horst Przuntek,Volker Hoffmann,Christopher T. Bever,Eleanor Katz,Michel Clanet,Isabelle Berry,David Brassat,Irene Brunet,Gilles Edan,Pierre Duquette,Ernst Wilhelm Radue,Dagmar Schött,Carmen Lienert,Alice Taksaoui,M. Rodegher,Massimo Filippi,Alan C. Evans,Pierre Bourgouin,Alex P. Zijdenbos,Shawki Salem,Nicholas Ling,David G. Alleva,Eric B. Johnson,Amitabh Gaur,Paul D. Crowe,Xin-Jun Liu +46 more
TL;DR: There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions, and secondary analysis showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg.
Journal ArticleDOI
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Gilles Edan,David Miller,Michel Clanet,Christian Confavreux,Olivier Lyon-Caen,Catherine Lubetzki,Bruno Brochet,Isabelle Berry,Y Rolland,J C Froment,E A Cabanis,M.T. Iba-Zizen,J M Gandon,H M Lai,I. F. Moseley,O Sabouraud +15 more
TL;DR: In this selected group of patients with multiple sclerosis with very active disease, mitoxantrone combined with methylprednisolone was effective in improving both clinical and MRI indices of disease activity over a period of six months whereas methylpredisonsolone alone was not.
Journal ArticleDOI
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos,David W. Bates,Gilles Edan,Mefkure Eraksoy,Antonio Garcia-Merino,Nikolaos Grigoriadis,Hans Peter Hartung,Eva Havrdova,Jan Hillert,Reinhard Hohlfeld,Marcelo Kremenchutzky,Olivier Lyon-Caen,Ariel Miller,Carlo Pozzilli,Mads Ravnborg,Takahiko Saida,Christian Sindic,Karl Vass,David B. Clifford,Stephen L. Hauser,Eugene O. Major,Paul O'Connor,Howard L. Weiner,Michel Clanet,Ralf Gold,Hans H. Hirsch,Ernst W. Radü,Per Soelberg Sørensen,John King +28 more
TL;DR: This Review revisits and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.